Skip to content

The measurement of insulin sensitivity index in normoglycemic healthy Korean subjects

The measurement of insulin sensitivity index in normoglycemic healthy Korean subjects in their 6th and 7th decades using hyperinsulinemic euglycemic clamp study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003156
Enrollment
30
Registered
2018-09-03
Start date
2016-10-07
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Hyperinsulinemic-euglycemic clamp testing after a 10-hour fast was performed within 1 week following the oral glucose tolerance test (OGTT) in healthy adult male subjects with normal glucose to
Eli Lilly and Co., Indianapolis, IN, USA) was infused at a rate of 10 mU/m2·min for 100 min, and then a high dose of insulin (80 mU/m2·min) was applied for 100 min to suppress hepatic glucose producti
dextrose solution was administered to maintain euglycemia, and the plasma glucose levels were measured every 5 min. During the last 20 min at steady state with the plasma glucose level being maintaine

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Korean aged 50-69 years old 2) body weight 50kg or more with body mass index (kg/m2) 18.5-28 3) no congenital or systemic illnesses requiring medical care 4) no significant abnormal results on screening tests which included routine blood test and blood chemistry, urine test, ECG and physical examinations 5) subjects who provided written informed consent

Exclusion criteria

Exclusion criteria: 1) Subjects with impaired fasting glucose, impaired glucose tolerance, or diabetes or subjects on medical therapy for diabetes 2) Subjects who have hypersensitivity to insulin or preservatives of insulin 3) Subjects with specific diseases in hepatobiliary, renal, or cardiovascular systems, with endocrine disease, or with other systemic illnesses 4) active liver diseases or liver transaminase enzyme levels elevated more than twofold the upper limit of normal 5) patients with known hypertension or subjects with blood pressure levels of > 160/90 mmHg or < 90/60 mmHg. 6) systemic diseases or injury within 12 weeks 7) other study medication or intervention therapy within 3 months before oral glucose tolerance test 8) Positive result on tests for HBs antigen, HCV antibody, or HIV antibody 9) any other issue suggesting that study participation seems to be inappropriate

Design outcomes

Primary

MeasureTime frame
glucose disposal rate (mg/kg/min)

Secondary

MeasureTime frame
2 hour-glucose level after oral glucose loading (75grams)

Countries

Korea, Republic of

Contacts

Public ContactDAE HO LEE

Gachon University Gil Medical Center

drhormone@naver.com+82-32-458-2733

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026